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Abstract
Background: The benefits of scientific medicine have eluded millions in developing countries and the
genomics revolution threatens to increase health inequities between North and South. India, as a
developing yet also industrialized country, is uniquely positioned to pioneer science policy innovations to
narrow the genomics divide. Recognizing this, the Indian Council of Medical Research and the University
of Toronto Joint Centre for Bioethics conducted a Genomics Policy Executive Course in January 2003 in
Kerala, India. The course provided a forum for stakeholders to discuss the relevance of genomics for
health in India. This article presents the course findings and recommendations formulated by the
participants for genomics policy in India.
Methods: The course goals were to familiarize participants with the implications of genomics for health
in India; analyze and debate policy and ethical issues; and develop a multi-sectoral opinion leaders' network
to share perspectives. To achieve these goals, the course brought together representatives of academic
research centres, biotechnology companies, regulatory bodies, media, voluntary, and legal organizations
to engage in discussion. Topics included scientific advances in genomics, followed by innovations in
business models, public sector perspectives, ethics, legal issues and national innovation systems.
Results:  Seven main recommendations emerged: increase funding for healthcare research with
appropriate emphasis on genomics; leverage India's assets such as traditional knowledge and genomic
diversity in consultation with knowledge-holders; prioritize strategic entry points for India; improve
industry-academic interface with appropriate incentives to improve public health and the nation's wealth;
develop independent, accountable, transparent regulatory systems to ensure that ethical, legal and social
issues are addressed for a single entry, smart and effective system; engage the public and ensure broad-
based input into policy setting; ensure equitable access of poor to genomics products and services; deliver
knowledge, products and services for public health. A key outcome of the course was the internet-based
opinion leaders' network – the Indian Genome Policy Forum – a multi-stakeholder forum to foster further
discussion on policy.
Conclusion: We expect that the process that has led to this network will serve as a model to establish
similar Science and Technology policy networks on regional levels and eventually on a global level.
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Background
Over the last hundred years, innovations in medicine, sci-
ence and technology have resulted in improved health,
quality of life and a rise in life expectancy worldwide. In
light of this impressive record it is disheartening that the
benefits of scientific medicine continue to elude millions
of people in the poorer parts of the world [1]. Children
and adults are undernourished, live in poor housing and
die from illnesses that are often preventable in the prime
of their lives. India, with its wealth of scientific researchers
and medical professionals, has made impressive gains in
scientific medicine, but the health needs of the majority of
the population continue to be unmet.
India is a developing country with a population of over 1
billion, the majority of which live in poverty and have lit-
tle access to modern medicine. On the other hand, it is
counted among the most industrialized countries in the
world, with the largest pool of English-speaking scientific
and technical professionals outside the United States. It
has a well-established pharmaceutical industry. It also
continues to be the world leader in the information tech-
nology sector, which has spawned a burgeoning bioinfor-
matics industry. In fact, India's success in information
technology – its computer software and services industry
grew from about $500 million to more than $6 billion in
exports over the last decade – may provide a model for its
biotechnology aspirations [2]. However, it can be argued
that building biotechnology capability will be a more
challenging task. In order to achieve its biotech potential,
India will have to overcome some significant challenges,
including uncharted territory in regulatory issues, an
evolving intellectual property rights environment, and the
slow pace of integration between academic and private
sector science. Despite these hurdles, India has made
impressive forays into the biotechnology sector, both
through public sector efforts as well as industry
innovation.
In order to assess the potential of these advances to
address health needs in India, the Indian Council of Med-
ical Research and Joint Centre for Bioethics at the Univer-
sity of Toronto jointly organized a Genomics Policy
Executive Course, from January 20th–23rd, 2003, at Kuma-
rakom Lake Resort in Kerala, India. This 4-day course was
conducted by the Indian Council of Medical Research and
University of Toronto's Joint Centre for Bioethics, and
sponsored by ICMR, Genome Canada, and the Interna-
tional Development Research Centre. The primary goal of
the course was to familiarize participants with the poten-
tial of genomics and related biotechnologies to address
health needs in India and to collectively address the ques-
tion of how to best harness genomics to improve health
(Figure 1).
Methods
The program was planned by first preparing a schedule
with presentation topics. We based the layout of the ses-
sions and lecture topics on prior courses held in Nairobi,
Kenya in March 2002 and in Toronto, Canada in May
2002. The sessions and presenters are shown in Table 1.
Objectives of the Course Figure 1
Objectives of the Course
•  To familiarize participants with the current status and implications of
genomics and biotechnology for health in India, and to provide information
relevant to public policy
•  To provide frameworks for analyzing and debating the policy issues and
related ethical questions, and to help understand, anticipate and possibly
influence the legal and regulatory frameworks which will operate, both
nationally and internationally
•  To begin developing an opinion leaders’ network across different sectors
(industry, academic, government, and voluntary organisations) by sharing
perspectives and building relationshipsHealth Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
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Both course participants as well as presenters for each ses-
sion were identified through a combination of recom-
mendations from field experts in India and searches on
ICMR's database of experts. These efforts were augmented
by assistance from the Confederation of Indian Industry.
People identified to participate in the course included sci-
entists from academic centres and industry, industry exec-
utives, regulatory officials, representatives from the legal
sector, NGOs and media. The participants were carefully
chosen in an attempt to represent a wide range of interests
in the emerging area of genomics in India. In total there
were 52 participants, and the represented institutions are
listed in Figure 2.
The sessions dealt with a wide range of relevant topics,
starting with recent scientific advances in genomics and
stem cell research, followed by discussions on business
models in genomics and biotechnology, intellectual prop-
erty rights and regulatory frameworks, public engagement
and an internet-based opinion leaders' network. A
detailed time-table of the program is shown in Table 1.
The presentations were designed to be interactive and fos-
ter active discussion from the participants. Most present-
ers used Microsoft powerpoint presentations, or overhead
transparencies, and, where appropriate, additional visual
aids such as video films. Each session set aside at least 45
minutes for discussion and participation. Participants
were encouraged to read supporting materials (Figure 3)
prepared prior to the meeting (in consultation with pre-
senters) in order to enhance their in-class experience and
maximize the benefits from the presentations and the
class discussion. Materials included peer-reviewed articles,
as well as news items, patents, and material from other
sources. The facilitators (in particular PAS) summarized
the main points at the end of each lecture, facilitated the
discussion and maintained continuity and focus
throughout the course. Early in the course, the attendees
were placed into one of five study groups – these groups
were carefully chosen to capitalize on the diversity in
background and expertise of the participants. The overall
task of these study groups was to draw upon the course
material and their own experiences and propose a set of
recommendations for genomics and biotechnology policy
in India. The groups met frequently to discuss the presen-
tations, and each participant was also provided a course
reader with additional background reading materials on
the lecture topics. In order to assess the level of interest in
the formation of an email-based opinion leaders' net-
work, a brief survey was conducted on the participants'
internet access and their expectations of the network.
Results
The first day of the course introduced participants to one
another, and to the overall purpose and objectives of the
course (Figure 1). The day's presentations began following
the welcome address by conveners from ICMR and Uni-
versity of Toronto, and a brief overview of the status of
genomic research in India. The three presentations of the
day were dedicated to familiarizing the participants with
the latest scientific advances in genomics and biotechnol-
ogy, and their relationship to international health, partic-
ularly to health in developing countries. Dr S.S. Aggarwal,
Director ACTREC, presented background information on
genomics and discussed the revolution in life sciences that
Table 1: Program and Session Facilitators
Time Day 1 Day 2 Day 3 Day 4
9:00 – 10:30 Introduction and Course Overview
Dr Vasantha Muthuswamy – ICMR
Dr Peter A. Singer – University of Toronto
Dr Abdallah S. Daar – University of 
Toronto
Ethical guidelines for Medical 
Research in India
Dr N.K. Ganguly – ICMR
Intellectual Property Rights
Dr Malathi Lakshmikumaran – 
TERI
Opinion Leaders' Network
Dr Peter A. Singer
Dr Rakesh Dubey – Ocimum
Biosolutions
11:00–12:30 New Science 1 : Genomics
Dr S. S. Agarwal – ACTREC
DNA Vaccines – Relevance for India
Dr G. Padmanabhan – IISc
Business Models
Dr Chandu Nair – Scope 
Marketing & Knowledge
National Systems of Innovation
Dr Peter A. Singer
Public Health – Community 
Ownership
Dr Saraswathi Sankaran – 
DESH
2:00–3:30 New Science 2 : Stem Cells
Dr Dipika Mohanty – ICMR (Institute of 
Immunohaematology)
Indian Business Perspectives
Mr Khalil Ahmed – Shanta 
Biotech
Dr Krishna Ella – Bharath 
Biotech
Group Presentations
Biotechnology: From Benches 
to Bedside
Dr Rajesh Behl – Centre for 
Human Genetics
Group Presentations
4:00–5:30 Genomics and Global Health
Dr Abdallah S. Daar
Pharmaco-genomics
Dr C. M. Gupta – CDRI
Dr Vasantha Muthuswamy
Dr R. H. Jani – German 
Remedies
Legal Regulations of Genomics 
– Emerging Scenario
Dr Madhava Menon – WB 
National
University of Juridical Sciences
Summing up
Dr Sandhya Tewari – CII
Discussion & Closing – Dr 
Peter A. SingerHealth Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
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Participants and Affiliations Figure 2
Participants and Affiliations
A.D. Nageswari - Directorate of Medical Education, Chennai
Abdallah Daar - Joint Centre for Bioethics, University of Toronto
Alok Kumar - Proagro Seed Co. Pvt Ltd (Bayer CropScience) 
Asis Datta - International Centre for Genetic Engineering & Biology, JNU
C.M. Gupta - Central Drug Research Institute 
Chandu Nair - Scope marketing & Information Solutions Pvt Ltd
D.Varatharajan - Sree Chitra Tirunal Institute for Medical Sciences and Technology
Dinesh C. Sharma - The Lancet Oncology
Dipika Mohanty - Institute of Immunohaematology, ICMR
G. Padmanabhan - Indian Institute of Sciences (IISc)
G.S. Khatre - Bharat Biotech International Ltd 
Geeta Jotwani - ICMR 
Jai Rup Singh - Guru Nanak Dev University
K.Ramamoorthy - Kerala Government
Kasturi Dutta - Special Centre for Molecular Medicine, JNU
Khalil Ahmed - Shantha Biotechnics Pvt Ltd
Krishna Ella - Bharat Biotech International Ltd 
M. Jayaprasad - Malayala Manorama
Malathi Lakshmikumaran - Tata Energy Research Institute
Manoranjan Hota - Ministry of Environment & Forests 
Moinak Banerjee - Rajiv Gandhi Centre for Biotechnology
N.K. Ganguly - ICMR 
N.K. Mehra - All India Institute of Medical Sciences
N.R. Madhava Menon - West Bengal National University of Juridical Sciences
Nandini K. Kumar - ICMR 
P.R. Sudhakaran - Kerala University
P.S. Maruthi Sai - Dr Reddy’s Laboratories Ltd. 
Peter Singer - Joint Centre for Bioethics, University of Toronto
Poonam Salotra - Institute of Pathology, ICMR
Prochi Madon - Reliance Life Sciences Pvt. Ltd. 
R. S. Paranjape - National AIDS Research Institute, ICMR
R.H. Jani - German Remedies
Rajeev Soni - Ranbaxy Lab. Ltd 
Rajesh Behl - Centre for Human Genetics
Rakesh Dubey - Ocimum Biosolutions Ltd 
S. C. Sehgal - Regional Medical Research Centres, ICMR
S.S. Agarwal - Advanced Centre for Treatment, Research and Education in Cancer
Sandhya Srinivasan - freelance journalist
Sandhya Tewari - Confederation of Indian Industry
Sandip Basu - National Institute of Immunology 
Sachin Chaturvedi - Research & Information Systems
Sarala K. Subba Rao - Malaria Research Centre, ICMR
Saraswathi Sankaran - Deepam Educational Society for Health (DESH) 
Subbiah Arunachalam - M.S. Swaminathan Research Foundation
Sujatha Narayanan - Tuberculosis Research Centre, ICMR
Suman Sahai - Gene Campaign
T.S. Rao - Department of Biotechnology, Ministry of Science & Technology 
Tara Acharya - Joint Centre for Bioethics, University of Toronto
V. Mohanan Nair - Sree Chitra Tirunal Institute for Medical Sciences and Technology
V. Vasanthi - Directorate of Public Health and Preventive Medicine, Govt of Tamil Nadu 
Vasantha Muthuswamy – ICMR 
Vinod Varshney - Hindustan TimesHealth Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
Page 5 of 13
(page number not for citation purposes)
Readings used During the Course Figure 3
Readings used During the Course
Cahill, Lisa Sowle (2001) "Genetics, Commodification, and Social Justice in the Globalization 
Era", Kennedy Institute of Ethics Journal, 11(3), p. 221-238
Caulfied, Timothy, E. Richard Gold and Mildred K. Cho, "Patenting Human Genetic Material: 
Refocusing the Debate", Science and Society, [pages? year?]
Chaturvedi S (2002) Status and Development of Biotechnology in India: an Analytical 
Overview. http://www.ris.org.in/dp28_pap.pdf.
CIHR (January 2002) "Human Pluripotent Stem Cell Research: Recommendation for CIHR-
Funded Research", Report of the Ad Hoc Working Group on Stem Cell Research, 
www.cihr.ca/cgi-bin/cihr_print.pl
Collins, Beverly A. et al. (July 2000) "From Theory to Practice: Identifying Authentic Opinion 
Leaders to Improve Care", Managed Care, p. 56-62
Daar AS, Thorsteinsdottir H, Martin DK, Smith AC, Nast S, Singer PA. (2002) Top ten 
biotechnologies for improving health in developing countries. Nat Genet.;32(2):229-32.
Enriquez, Juan and Ray A. Goldberg (March-Arpil 2000) "Transforming Life, Transforming 
Business: The Life-Science Revolution", Harvard Business Review, p. 96-104
Gaskell, George et al. (September 2000) "Biotechnology and the European Public", Nature
Biotechnology, Vol 18, p. 935-938
ICMR (2000) Ethical Guidelines for Biomedical Research on Human Subjects. Indian Council 
of Medical Research. New Delhi 2000. http://icmr.nic.in/ethical.pdf
Lemmens, Trudo (1999) "Private Parties, Public Duties: The Shifting Role of Insurance 
Companies in the Genetics Era", Genetic Information: Acquisition, Access and Control, Alison
Thompson and Ruth Chadwick, Eds, Kluwer Academic/Plenum Publis, p. 31-39
Lemmens, Trudo (March 1997) "What About Your Genes?" Ethical, Legal, and Policy 
Dimensions of Genetics in the Workplace", Politics and the Life Sciences, 16(1), p. 57-75
Melzer, David (1998) "Patent Protection for Medical Technologies: Why some and not 
others?", Lancet, Vol 351, p. 518-19
Owens, Kelly and Mary-Claire King (October 1999) "Genomic Views of Human History", 
Science, Vol 286, p. 451 - 453
Pang T & Weatherall D (2002) Genomics and Global Health. BMJ Vol 324, 4
th May p.1051-52
Roses, Allen D. (June 2000) "Pharmacogenetics and the Practice of Medicine", Nature, Vol 
405, p. 857-865
Scherer, Stephen (Autumn 2001) "The Human Genome Project", ISUMA, p. 11 - 19
Singer PA, Daar AS. (2001) Harnessing genomics and biotechnology to improve global health 
equity. Science;294(5540):87-9.
Wolf, Susan M. (1995) "Beyond "Genetic Discrimination": Toward the Broader Harm of 
Geneticism", Journal of Law, Medicine and Ethics, 23, p. 345-53Health Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
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genomics has brought about. Dr G. Padmanabhan, Emer-
itus Scientist, Indian Institute of Science spoke on the rel-
evance of DNA vaccines have been heralded as third
vaccine revolution and how developing countries like
India should develop it as a cost-effective alternative with
indigenous expertise and international help. Dr Dipika
Mohanty of the Institute of Immuno-haematology at KEM
hospital brought the participants up to speed on the latest
research in stem cells. Dr Abdallah Daar of the University
of Toronto Joint Centre for Bioethics closed the day with
a discussion of the impact of genomics and related bio-
technologies on global health, emphasizing the ten bio-
technologies that are the best candidates to address the
health needs of developing countries [3]. A rich discus-
sion followed each session, with participants focusing on
both the latest scientific developments, as well as their
potential impact for health in the developing world, in
particular India. Some participants were enthusiastic
about these developments, while others remained scepti-
cal about the immediate benefits for the developing
world.
On the second day, Dr N.K. Ganguly, Director-General of
ICMR, presented an overview of the progress of biotech-
nology in India and the need for a revision of ethical
guidelines in medical research, emphasizing the need to
link science and society, allocation of resources for health,
and the disconnect between industrial policy and health
policy in India. This lecture was followed by a focus on
industry perspectives, with an introduction on worldwide
business models in the biotechnology sector by Mr
Chandu Nair, Director, Scope e-knowledge Centre. Dr
Peter Singer of the University of Toronto then discussed
the concept of national systems of innovation, with exam-
ples from the industrialized world (Canada and the
United States) as well as emerging economies like India
and Cuba. Mr Khalil Ahmed, Executive Director at Shan-
tha Biotech and Dr Krishna M. Ella director Bharat Biotech
provided the participants with their own concrete exam-
ples from the perspective of the Indian biotechnology
industry, bringing into the spotlight the importance of
private enterprise in the quest for global health equity.
The day ended with a discussion of pharmacogenomics
and its potential for improving health in India, presented
by Drs R. H. Jani, MD German Remedies, and C. M.
Gupta, Director, CDRI and the ethical issues pertaining to
this new area presented by Dr Vasantha Muthuswamy.
This day saw animated discussions on collaborations
between the public and private sectors to foster biotech-
nology in India, as well as the role of government policy
in encouraging investment in the private sector and
academia. There was also a discussion of ethics, confiden-
tiality and privacy issues and intellectual property rights
triggered by the session on pharmacogenomics.
The third day opened with an interactive session on intel-
lectual property rights, led by Dr Malathi Lakshmikuma-
ran of TERI, which generated a good deal of debate on
traditional knowledge and its ownership. Dr Saraswati
Sankaran then brought to light the importance of public
engagement to realize the potential of biotechnology in
health improvement, using the example of her Organisa-
tion DESH's HIV/AIDS initiative. This talk was followed
by group work and a discussion by the participants, on
public engagement interventions for biotechnology based
on the role of the settings assigned to each group (Media;
Educational institutions; Hospitals; Workplace; Slum-
dwellers). Some of the practical suggestions from the par-
ticipants included school field trips to biotechnology lab-
oratories and training in the workplace on ethical
concerns regarding genetic profiling. Dr Madhava Menon
then presented a discourse on the emerging scenario
regarding the legal regulation of genomics and its impor-
tant inclusion in juridical sciences. Dr Rajesh Behl from
the Center for Human Genetics, Bangalore, followed with
a lecture on how best to translate the benefits of basic
scientific research to practical medical interventions. This
intensive day ended with the participants working in
groups to use the material that had been presented in the
course in order to address the underlying question: how to
harness the benefits of genomics and biotechnology to
improve health in India.
The final day of the course set out with Drs Rakesh Dubey
of Ocimum Biosolutions and Peter Singer presenting their
thoughts on the proposed internet-based Opinion Lead-
ers' Network – the main goal of which is to encourage fur-
ther interaction between the participants (as well as other
interested individuals) with an overarching aim to create
sound genomics policy in India. Both noted that it would
be essential to have wide representation, active participa-
tion from all sectors and open discussion. A survey was
conducted to assess the participants' level of interest in
establishing such a network, and what they expect to
achieve from it. Following this, the participants were
given three hours to work on their presentations, and the
course re-convened after lunch.
The five groups were each given the opportunity to
present their views of the most important aspects of the
course, and how best to use genomics and biotechnology
to address India's health needs. While it was generally
agreed that the biotechnology sector (encompassing both
public and private efforts) has grown over the last ten
years and that genomics has the potential to alleviate
India's health problems, the course participants also
emphasized the importance of effective regulatory sys-
tems, intellectual property rights and ethical and social
issues related to genomics and public health. In his role as
facilitator, Peter Singer then identified recurring themes inHealth Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
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these presentations and synthesized them into seven over-
all recommendations for genomics policy in India. An
intensive debate followed, as participants deliberated over
these recommendations with regard to their suitability to
the Indian economy, health needs and the biotechnology
sector. The recommendations were modified accordingly
by the participants. The final recommendations emerged
over the course of the debate (Figure 4), and these will be
discussed further below.
Discussion
Increase funding for healthcare research with appropriate 
emphasis on genomics
Currently, the total funding for health research in Central
governmental institutions in India is a little over US $100
million – these funds are allocated to the control of
communicable and non-communicable diseases, patient
care, medical education, training, and research with the
latter three accounting for about 60% of the funds [4]. In
contrast, the budget for the US National Institutes of
Health for basic biosciences R&D alone was $23.6 billion
in 2002, or about 1% of the total US government budget
[5]. Therefore, even though India's purchasing power par-
ity inflates this level of funding, it still represents less than
0.5% of the total budget (approximately $92 billion for
the year 2003–4).
Not surprisingly, therefore, there was consensus among
the course participants that the Indian government needs
to increase funding for health research, with appropriate
emphasis on genomics and related biotechnology. The
Department of Biotechnology (under the Ministry of Sci-
ence and Technology) and the Indian Council of Agricul-
tural Research (ICAR) have also stressed the importance of
increased government funding for biotechnology research
and development in general and are requesting US $560
million for R&D from the federal government for the
tenth five-year plan. These funds will be used for ongoing
and new programs in vaccine research, genomics, trans-
genic plants and animals, and technology transfer. The
DBT also expects to support state governments in building
biotechnology parks and research centres [6].
The private sector, for its part, has also faced financial hur-
dles. Biotechnology companies have found it difficult to
attract both government as well as venture capitalist fund-
ing (Indian survey). This is partly due to the perception of
biotechnology market as uncertain, especially over the last
Recommendations Emerging from the Course Discussion Figure 4
Recommendations Emerging from the Course Discussion
• Increase funding for healthcare research with appropriate emphasis on genomics
• Leverage India’s assets such as traditional knowledge and genomic diversity in
consultation with knowledge-holders and indigenous communities
• Prioritize strategic entry points for India as per the national innovation system
• Improve industry-academic interface with appropriate incentives to improve public
health and the nation’s wealth
• Develop independent, accountable, transparent regulatory systems based on
ethics to ensure that ethical, legal and social issues are addressed for a single
entry, smart and effective system
• Engage the public and ensure broad-based input into policy setting
• Ensure equitable access of poor to genomics products and services
• Deliver knowledge, products and services for public health
• Establish an internet-based opinion leaders’ network to foster cross-sectoral
dialogueHealth Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
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two years, but there was considerable debate during the
course over the fact that funding for R&D in the biological
sciences has been directed mostly at the public sector,
with few incentives for the private sector. Key govern-
ment-funded research centres in India include the Indian
Council for Medical Research; the National Centre for
Biological Sciences in Bangalore (owned by the Tata
group); the Tata Institute for Fundamental Research; the
Centre for Cellular and Molecular Biology. ICMR is
expected to receive US $30 million over five years from
the Ministry of Health for genomics, stem cell and struc-
tural biology research. The funding will be divided among
various research centres and medical institutions under
the direction of ICMR, and will focus, among other
diseases, on leprosy, TB, rheumatic fever and β-tha-
lassemia [7].
Leverage India's assets such as traditional knowledge and 
genomic diversity in consultation with knowledge-holders 
and indigenous communities
India has 7% of the world's biodiversity and with it a
treasure of traditional knowledge of the medicinal proper-
ties of indigenous plants [8]. Moreover, the genetic diver-
sity of the population makes the country a tremendous
source of information for research in genetic epidemiol-
ogy. The Indian Genome Initiative (IGI) is a project
launched by the DBT to study the genetic variation of the
Indian population. The program has funding support of
US $20 million over five years. A network of four gene
banks has also been set up for the conservation of rare,
endangered and commercially important medicinal and
aromatic plants, and a program has been initiated for the
development of herbal products with the help of biotech-
nology tools [6]. Dr Malathi Lakshmikumaran's presenta-
tion of India's successes in overturning the Basmati rice
and turmeric patents highlighted the issue of intellectual
property rights over traditional knowledge in developing
countries. The former patent was seen as a serious eco-
nomic threat for rice exporters from India and Pakistan. In
1997, the Texas-based firm RiceTec was granted a patent
on 'basmati rice lines and grains' by the USPTO on the
basis of 20 claims. India and Pakistan challenged three of
the claims that related to the grain quality (such as elon-
gation in cooking and the characteristic aroma of basmati
grains). Following re-examination of the patent, Rice Tec
has withdrawn these claims and can no longer use the
name "Basmati" for its rice lines. The turmeric patent was
seen as a rather opportunistic attempt to own exclusive
rights to a natural product that has been used in India for
medicinal purposes for centuries. In 1995, two U.S. based
Indians were granted a patent for the use of turmeric in
wound healing. The invention claimed under the patent
was the use of turmeric at the site of an injury and/or its
oral intake to promote the healing of a wound. An exten-
sive search yielded indigenous medical texts, some over
100 years old, that challenged the novelty of the use of tur-
meric in healing wounds, leading the USPTO to revoke
the patent.
The value of these traditional assets is widely recognized,
and the participants acknowledged that they need ade-
quate protection and benefit sharing so that indigenous
communities are not exploited and are the recipients of
the products of research conducted on them. According to
the DBT, sixteen genetic diagnosis and counselling units
have been set up in the country for prenatal diagnosis and
counselling for major genetic disorders. Almost fourteen
thousand affected families have benefited from this pro-
gramme. A few thousand people belonging to socially
underprivileged groups have been screened for detecting
various genetic disorders. A National Bioethics Commit-
tee has formulated policies for the ethics of research in
human genetics and genomics, and ICMR guidelines on
human genetics have been legislated. The DBT has also
developed policies on ethics and regulatory issues in bio-
technology [9].
Prioritize strategic entry points for India as per the 
national innovation system
As India makes forays into genomics and bioinformatics,
it will be important to prioritize the country's health
needs and strategic entry points. An estimated 4 million
people are living with AIDS in India [10], over 2 million
people are infected with malaria per year [11] and over
420,000 Indians die annually from tuberculosis [12]. On
the other hand, chronic diseases like cancer, diabetes and
heart disease are also prevalent in India and pose a rising
health concern. Both these broad categories of disease
present R&D opportunities for India. Moreover, India's
biotechnology and pharmaceutical industries are also in a
good position to prioritize and develop indigenous tech-
nologies. For example, the announcement by the US
Department of Health in 2002 of 64 stem-cell lines that
will be funded by the US federal government creates
opportunities for stem cell research in India – Reliance
Life Sciences has 7 of these cell lines. The Indian biotech-
nology industry is ranked third in the world in terms of
stem cell research, primarily because both the government
and private industry have invested heavily in research
institutes studying stem cells. The World Health Organiza-
tion, in its 2002 report on Genomics and World Health,
also urges Member states to build genomics and bioinfor-
matics capacity for research towards their own health pri-
orities in order to address global health inequities [13].
India can, and has already begun to, translate its successes
in software technology into bioinformatics capability.
In January 2002, the DBT also articulated priority research
areas for government funding in biotechnology. These
areas include vaccines based on genomic research forHealth Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
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cholera, malaria, AIDS, rabies and tuberculosis as well as
biofertilizers, biopesticides, transgenic crops, and gene
therapy for cancer treatment. A biotechnology vision doc-
ument released in late 2001 outlines additional plans over
the next 10 years and includes developing edible vaccines
for specific disease targets, testing and approving a series
of GM crops, developing additional vaccines and
diagnostic tools for major communicable diseases, as well
identifying and protecting biodiversity "hot spots."
There is considerable concern among NGOs and other
stakeholders in India that the DBT's goals are too broad
and difficult to realize. Moreover, it is doubtful that these
activities will help to meet the health needs of the
economically weaker sections of society. It is widely felt,
and this sentiment was echoed during the course, that
India needs a clearly articulated genomics and biotechnol-
ogy policy that will focus biotechnology research on
domestic needs.
In February 2001, ICMR launched a genome initiative and
approved 101 out of 167 proposals for research at centres
for molecular medicine and bioinformatics units in areas
including vaccines, microbial genomics, vector genomics,
molecular genetics of haematological disorders, popula-
tion genetics, pharmacogenetics, nutrition genomics, and
neurogenetics.
Private sector efforts in biotechnology have so far focused
mainly on the development of vaccines and therapeutic
recombinant proteins for infectious diseases. A number of
biotechnology products are in various stages of develop-
ment. Hyderabad-based Shantha Biotech's recombinant
hepatitis-B vaccine was launched in 1997, and in 2002
Shantha also launched alpha-interferon "Shanferon" in
parts of the country. Shantha Biotechnics has recently
become the first Indian company to obtain World Health
Organization certification of the hepatitis-B vaccine,
opening the way for entities like UNICEF to purchase this
low-priced product for their programs. Last year, UNICEF
ordered 8.5 million doses of Shanvac B, worth $5 million,
for worldwide distribution. Another promising Indian
biotechnology company is Hyderabad-based Bharat Bio-
tech International, which launched its brand of hepatitis-
B vaccine, Revac-B, in January last year. Bharat Biotech
boasts a production capacity of 100 million doses, possi-
bly the largest in the Asia-Pacific region [14].
Improve industry-academic interface with appropriate 
incentives to improve public health and the nation's 
wealth
A recurring theme throughout the course discussions was
the public-private interface in health research, and how to
create greater fluidity between the two while simultane-
ously ensuring incentives for industry growth and improv-
ing public health. The United States appears to present
one successful model of a fluid industry-academic inter-
face, wherein an academic discovery can be leveraged to
launch a commercial product – the earliest such example
in biotechnology being Genentech which pioneered the
industry through the commercial application of recom-
binant DNA techniques [15].
The biotechnology industry is capital intensive, and the
funds required for biomedical research can often be mobi-
lized only with the help of the private sector. Forging pub-
lic-private partnerships will allow the public sector to
have access to some of these funds, and allow private
companies access to public resources.
There was considerable debate among the participants on
striking a balance between improving public health in
India while at the same time ensuring that commercial
incentives remain strong and India's economic growth,
particularly in the area of scientific research and biotech-
nology, is not hampered.
The Government of India has introduced some incentives
for the biotechnology industry, for example it now
emphasizes upgrading scientific research and allows duty
free import of selected equipment for biotechnology
research. In his inaugural address at the 90th session of the
Indian Science Congress, the Indian prime minister A.B.
Vajpayee also appealed to the private sector to "invest
more in indigenous R&D, in partnership with our S&T
institutions, IITs (Indian Institutes of Technology) and
universities, so that their products and services become
globally competitive" [16]. Vajpayee also mentioned the
disturbing phenomenon of "brain-drain" – both the
migration of talented Indian scientists and technologists
to developed countries, as well as the diversion of talent
away from R&D careers to non-scientific careers in both
Government and the private sector. He stressed the need
to take concrete steps to give promising scientists and
technologists the necessary opportunities, recognition,
and adequate material compensation.
The DBT maintains that it has promoted and accelerated
the pace of development of biotechnology in India – but
a criticism of its policies is that these incentives have been
aimed largely at government-supported research centres.
Meanwhile, according to a market assessment report by
Canada's Department of Foreign Affairs and International
Trade, there are as many as 175 biotechnology companies
active in the Indian market; up to 50 of those companies
work on advanced biotechnology applications [17].
Approximately 60% of the industry is devoted to human
health applications, 10% to agricultural biotechnology
and 30% to industrial applications, bioinformatics and
genomics. Increased collaboration between companiesHealth Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
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and the public sector may accelerate growth of the indus-
try while at the same time focusing development in the
areas of greatest need.
In 2001, the Malaria Vaccine Initiative at PATH (Program
for Appropriate Technology in Health, a US-based non-
profit organization), the New Delhi site of the Interna-
tional Centre for Genetic Engineering and Biotechnology
(ICGEB), and the biotechnology firm, Bharat Biotech
International Limited in Hyderabad, India, announced an
agreement to jointly develop a vaccine with the potential
to prevent malaria caused by the parasite Plasmodium
vivax, transmitted through mosquito bites [18]. Nearly 65
percent of all malaria cases in India are caused by P. vivax.
This type of public-private partnership is encouraging for
public health in developing countries.
Develop independent, accountable, transparent 
regulatory systems to ensure that ethical, legal and social 
issues are addressed for a single entry, smart and effective 
system
Genomics is a rapidly evolving science that has the poten-
tial to be beneficial to public health but could also be mis-
used and carries with it a number of ethical, legal and
social implications. For example human genetic profiling
data could be used to discriminate against individuals in
terms of their employment or eligibility for health insur-
ance. This and other eventualities require the establish-
ment of an effective, transparent and accountable
regulatory system. The field of genomics has an impact on
basic human rights – to life, equality, information, choice
and privacy. It also raises other legal issues such as trade
and intellectual property rights. It is, therefore, the func-
tion of an effective regulatory system to balance commer-
cial interests with human rights.
The regulatory system in India for biotechnology products
has been criticized by the All India Biotechnology Associ-
ation (established in 1994 as a non-profit society to repre-
sent the interests of all those engaged in various aspects of
biotechnology) for being bureaucratic and secretive[19].
AIBA has called for a fundamental re-structuring of the
regulatory system and for additional private sector
resources as a way to stimulate growth in the industry. It
has also proposed a national regulatory agency for all bio-
technology products under direct authority from the
prime minister and independent of various government
departments and ministries in order to reduce time for
regulatory approval. This is one possible solution, but
some course participants disagreed with the notion of a
single regulatory body, pointing out that the different
pace of development of the biotechnology sector in vari-
ous states in India may require state-specific regulatory
systems.
Dr Madhava Menon's suggestion at the Genomics Policy
course of the Telecommunications Regulatory Authority
of India (TRAI) serving as a potential model for biotech-
nology regulatory reform was met with some enthusiasm.
The aim of this endeavor is to transfer the regulatory pow-
ers of the government to TRAI for most purposes, such as
determining tariffs, monitoring revenue-sharing between
operators (including the Government's Department of
Telecommunications), settling disputes between opera-
tors and protecting consumer rights. While this may not
be the ideal model for biotechnology, it does, along with
AIBA's recommendations, provide the impetus and
rationale for an autonomous regulatory body within a
market economy.
Engage the public and ensure broad-based input into 
policy setting
Good public policy is based on informed public opinion
and the process of public engagement is closely linked
with consensus-building and policy formulation. The goal
of public engagement is to elicit a broad range of opinions
on contentious issues in genomics, such as genetic testing,
GM foods and intellectual property rights. Issues related
to genomics and biotechnology should therefore be pub-
licized to and discussed by a broad audience of stakehold-
ers, including scientists, regulatory officials, lawyers,
journalists, the private sector and consumers. For
instance, it will be vital to engage and educate the public
on developments in genomics in order to encourage
acceptance of novel biotechnology products as they reach
the market. Dr Saraswathi Sankaran brought to light the
importance of public engagement to realize the potential
of biotechnology in health improvement, using lessons
learned from the experience of the non-governmental
organization Deepam Educational Society for Health
(DESH) in health awareness promotion. DESH's pro-
grams are conducted in three phases: information and
awareness; empowerment with accountability; and collec-
tive, community action. Following this presentation, the
participants discussed the importance of genomics and
public engagement in various settings, such as hospitals,
educational institutions, the workplace, media and slum-
dwellers. This helped to highlight informational require-
ments specific to each setting, making it clear that broadly
representative input within policy decision-making bod-
ies would help to formulate genomics policy that is well-
grounded in societal needs. The participants made a
number of valuable suggestions, one of them being the
possibility of setting up multilingual websites for public
education as well as consultation.Health Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
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Deliver knowledge, products and services for public health 
and ensure equitable access of the poor to genomics 
products and services
India is uniquely positioned as a developing country with
strong biotechnology capabilities to set an example in
ensuring equitable access of its poor to biotechnology
products. Indian scientific and medical expertise can con-
tribute to the effort to address these health needs using the
latest advances in genomics and biotechnology, and the
Indian market represents opportunities to supply vaccines
and therapeutics to poor consumers – but at what cost?
There was no question among the course attendees that
ensuring access of the poor to these products is a daunting
task. This is where the government may have to take the
lead role in striking a balance, providing appropriate
incentives for the biotechnology industry while at the
same time ensuring equitable access to biotechnology
products. Again, India's biotechnology policy will be cru-
cial to the achievement of equitable access.
Shantha Biotech, which was first to launch the indige-
nously developed hepatitis-B vaccine in the country in
1997, has secured the WHO certification for its product
"Shanvac B" (now marketed at "Hepashield"). Shantha is
the only company in India to get this certification for the
hepatitis-B vaccine, and it is being provided at a quarter
the price of the previously imported vaccine [20].
Although this price still puts it out of reach of the poorest
Indians, more people have access to Shantha's product
than to the imported vaccine. This suggests that building
the private sector in India may help to improve access to
biotechnology products that would otherwise have to be
imported.
Opinion leaders' network
There was unanimous endorsement on the part of the
course attendees of the formation of an opinion leaders'
network that will serve as a forum to discuss the issues
mentioned above and arrive at some policy decisions, and
perhaps allow for policy papers that can be presented to
the Government of India for further action. The internet-
based network will be moderated in order to streamline
discussions. A number of short-term projects are envi-
sioned that could be coordinated by various expert mem-
bers of the network. The results of a survey administered
to the participants during the course suggested that 90%
of them had reliable access to internet and would be will-
ing to spend 1–2 hours a week taking part in the discus-
sion. The main objectives of the network, as identified by
the participants in the survey, would be dissemination of
information, exchange of ideas, maintaining inter-con-
nectivity, consensus building through wide participation,
and influencing policy and media. Other key results from
the survey are summarized in table 2 below.
Conclusion
Health advances in developing countries have lagged
behind those in the developed world. The rapid advance
in genomics research in developed countries compared
with the relatively slow progress of genomics R&D in
developing countries threatens to create a North-South
genomics divide in the coming years, which may enhance
existing health inequities. India has the unique
opportunity, as a developing country with highly skilled
scientists and medical professionals, to play a leadership
role in closing the genomics divide. With the appropriate
emphasis on its health needs, incentives for public-private
R&D partnerships, and a sound set of regulatory policies,
India may well set an example for the rest of the world.
The overall goal of the Genome Policy Executive Course,
an Indo-Canadian initiative, was to help provide the
impetus for cross-sectoral dialogue on genomics and
health policy in India.
Table 2: Opinion Leaders' Network Survey Results
Goals of network • Dissemination of information
• Exchange of ideas
• Maintaining inter-connectivity
• Consensus building through wide participation
• Influencing policy and media
Access • 24 (89%) no access issues – reliable connectivity from home/work
• 3 needed some assistance with email access (internet connection at work; compensation for access; 
help to post responses)
Obstacles to participation • 23 (85%) identified lack of time due to professional responsibilities.
• Most people willing to dedicate 1 hour a week to the network.
• 1 person stated inability to impact policy would discourage him/her from participating in the 
network
• 3 people had no time/work constraints for participationHealth Research Policy and Systems 2004, 2 http://www.health-policy-systems.com/content/2/1/1
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Research and development in genomics in developing
world will follow its path with or without courses of this
nature. The main limitation of a course of this nature is
the difficulty in maintaining focus with interdisciplinary
discussion and achieving consensus in a large group with
varying perspectives. However, it is a window into, and a
seed for well-informed inter-sectoral policy formulation.
Where this course is useful is in fostering a
multidisciplinary discussion that can contribute to policy
formulation by bringing together individuals from differ-
ent sectors and exposing them to alternative perspectives.
The key advantage of this course is that it can help bring
policy to the forefront so that ethical, social, and legal
aspects of new technologies do not lag behind as science
forges ahead. Without sound policy that keeps up with
new science, its benefits will be difficult to realize, and its
risks contained.
Although there are clearly some unique aspects to our
experience in India, it appears that the conceptual frame-
work of the course can be applied to other regions too.
Two other courses have been held, one in Africa and the
other in the Middle East. The Africa course, held in Nai-
robi, Kenya in March 2002, was attended by representa-
tives from 10 different nations. Its main themes for
discussion included the need for capacity-strengthening,
financial investment for R&D and commercialization, the
role of cross-sectoral partnerships, the need to engage gov-
ernment and also to educate the public. A similar internet-
based network, the African Genome Policy Forum, has
also been established. More recently, a similar course was
jointly organized with the World Health Organization's
Eastern Mediterranean Regional Office and held in Mus-
cat, Oman to serve the countries of the region (it was
attended by representatives from 13 countries). A concrete
recommendation emerging from the course is the creation
of National Biotechnology Councils in each country,
which will undertake, among other things, formulation of
national biotechnology policy. Two other courses, in
Latin America and in China, are being planned and will be
held in 2004.
While the experience in India may not be exactly the same
as in other regions of the world, there is some evidence
that a similar framework, with appropriate modifications
to session topics and participant representation could be
held elsewhere too. For instance, our procedure has now
led to three courses in three regions, with the formation of
regional networks in each place – Africa, India, and the
Eastern Mediterranean Region (where the course was
organized jointly with the World Health Organization's
Eastern Mediterranean Regional Office). Similar courses
are now being planned for Latin America and China. The
regional genome policy networks can provide models to
establish a Global Genome Policy Forum.
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